Eris Lifesciences Limited

NSEI:ERIS Stock Report

Market Cap: ₹219.4b

Eris Lifesciences Future Growth

Future criteria checks 4/6

Eris Lifesciences is forecast to grow earnings and revenue by 31.8% and 14.8% per annum respectively. EPS is expected to grow by 31.2% per annum. Return on equity is forecast to be 19.9% in 3 years.

Key information

31.8%

Earnings growth rate

31.21%

EPS growth rate

Pharmaceuticals earnings growth16.2%
Revenue growth rate14.8%
Future return on equity19.94%
Analyst coverage

Good

Last updated20 Nov 2025

Recent future growth updates

Eris Lifesciences Limited (NSE:ERIS) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Nov 15
Eris Lifesciences Limited (NSE:ERIS) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Earnings Miss: Eris Lifesciences Limited Missed EPS By 5.9% And Analysts Are Revising Their Forecasts

May 23
Earnings Miss: Eris Lifesciences Limited Missed EPS By 5.9% And Analysts Are Revising Their Forecasts

Analysts Are Updating Their Eris Lifesciences Limited (NSE:ERIS) Estimates After Its Third-Quarter Results

Feb 09
Analysts Are Updating Their Eris Lifesciences Limited (NSE:ERIS) Estimates After Its Third-Quarter Results

Eris Lifesciences Limited Just Missed EPS By 8.6%: Here's What Analysts Think Will Happen Next

Oct 30
Eris Lifesciences Limited Just Missed EPS By 8.6%: Here's What Analysts Think Will Happen Next

Recent updates

Eris Lifesciences Limited (NSE:ERIS) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Nov 15
Eris Lifesciences Limited (NSE:ERIS) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Is Eris Lifesciences Limited (NSE:ERIS) Worth ₹1.8k Based On Its Intrinsic Value?

Aug 28
Is Eris Lifesciences Limited (NSE:ERIS) Worth ₹1.8k Based On Its Intrinsic Value?

Here's Why Eris Lifesciences (NSE:ERIS) Can Manage Its Debt Responsibly

Jul 26
Here's Why Eris Lifesciences (NSE:ERIS) Can Manage Its Debt Responsibly

Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS) As Its Stock Soars 26%

Jun 17
Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS) As Its Stock Soars 26%

Eris Lifesciences' (NSE:ERIS) Conservative Accounting Might Explain Soft Earnings

May 26
Eris Lifesciences' (NSE:ERIS) Conservative Accounting Might Explain Soft Earnings

Earnings Miss: Eris Lifesciences Limited Missed EPS By 5.9% And Analysts Are Revising Their Forecasts

May 23
Earnings Miss: Eris Lifesciences Limited Missed EPS By 5.9% And Analysts Are Revising Their Forecasts

Why We're Not Concerned About Eris Lifesciences Limited's (NSE:ERIS) Share Price

Apr 28
Why We're Not Concerned About Eris Lifesciences Limited's (NSE:ERIS) Share Price
User avatar

Semaglutide Launch Will Secure Early Position In India's GLP-1 Market

Strategic GLP-1 market entry and Bhopal facility ramp-up are expected to boost revenue and margins through innovation and operational efficiency.

These 4 Measures Indicate That Eris Lifesciences (NSE:ERIS) Is Using Debt Reasonably Well

Mar 03
These 4 Measures Indicate That Eris Lifesciences (NSE:ERIS) Is Using Debt Reasonably Well

Analysts Are Updating Their Eris Lifesciences Limited (NSE:ERIS) Estimates After Its Third-Quarter Results

Feb 09
Analysts Are Updating Their Eris Lifesciences Limited (NSE:ERIS) Estimates After Its Third-Quarter Results

What You Can Learn From Eris Lifesciences Limited's (NSE:ERIS) P/E

Jan 07
What You Can Learn From Eris Lifesciences Limited's (NSE:ERIS) P/E

Here's Why Eris Lifesciences (NSE:ERIS) Can Manage Its Debt Responsibly

Nov 21
Here's Why Eris Lifesciences (NSE:ERIS) Can Manage Its Debt Responsibly

Eris Lifesciences Limited Just Missed EPS By 8.6%: Here's What Analysts Think Will Happen Next

Oct 30
Eris Lifesciences Limited Just Missed EPS By 8.6%: Here's What Analysts Think Will Happen Next

A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)

Oct 15
A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)

Eris Lifesciences Limited's (NSE:ERIS) CEO Compensation Looks Acceptable To Us And Here's Why

Sep 19
Eris Lifesciences Limited's (NSE:ERIS) CEO Compensation Looks Acceptable To Us And Here's Why

Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS) As Its Stock Soars 27%

Sep 03
Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS) As Its Stock Soars 27%

Earnings Update: Eris Lifesciences Limited (NSE:ERIS) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

Aug 05
Earnings Update: Eris Lifesciences Limited (NSE:ERIS) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly

Aug 04
Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly

Estimating The Intrinsic Value Of Eris Lifesciences Limited (NSE:ERIS)

Jul 13
Estimating The Intrinsic Value Of Eris Lifesciences Limited (NSE:ERIS)

Eris Lifesciences Limited (NSE:ERIS) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

May 24
Eris Lifesciences Limited (NSE:ERIS) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Why We're Not Concerned About Eris Lifesciences Limited's (NSE:ERIS) Share Price

May 10
Why We're Not Concerned About Eris Lifesciences Limited's (NSE:ERIS) Share Price

An Intrinsic Calculation For Eris Lifesciences Limited (NSE:ERIS) Suggests It's 25% Undervalued

Mar 14
An Intrinsic Calculation For Eris Lifesciences Limited (NSE:ERIS) Suggests It's 25% Undervalued

Analyst Estimates: Here's What Brokers Think Of Eris Lifesciences Limited (NSE:ERIS) After Its Third-Quarter Report

Feb 15
Analyst Estimates: Here's What Brokers Think Of Eris Lifesciences Limited (NSE:ERIS) After Its Third-Quarter Report

Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS)

Dec 28
Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS)

Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly

Dec 07
Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly

Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?

Nov 11
Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?

Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?

Jul 20
Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?

Does Eris Lifesciences (NSE:ERIS) Have A Healthy Balance Sheet?

Nov 20
Does Eris Lifesciences (NSE:ERIS) Have A Healthy Balance Sheet?

These 4 Measures Indicate That Eris Lifesciences (NSE:ERIS) Is Using Debt Safely

Jun 20
These 4 Measures Indicate That Eris Lifesciences (NSE:ERIS) Is Using Debt Safely

Earnings and Revenue Growth Forecasts

NSEI:ERIS - Analysts future estimates and past financials data (INR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/202843,2669,22110,88513,02910
3/31/202738,1367,3759,41111,59010
3/31/202632,8775,0965,5508,36410
9/30/202529,8644,1516,0448,190N/A
6/30/202529,3523,865N/AN/AN/A
3/31/202528,7933,5189,10010,650N/A
12/31/202427,2393,294N/AN/AN/A
9/30/202424,8533,4855,9317,068N/A
6/30/202422,4693,803N/AN/AN/A
3/31/202419,9133,9213,5694,860N/A
12/31/202318,4063,864N/AN/AN/A
9/30/202317,7503,856-3,3024,446N/A
6/30/202317,2983,824N/AN/AN/A
3/31/202316,6183,822-5,4972,917N/A
12/31/202215,6633,970N/AN/AN/A
9/30/202214,7663,9594192,844N/A
6/30/202213,7463,940N/AN/AN/A
3/31/202213,2624,0612,5723,783N/A
12/31/202112,9933,941N/AN/AN/A
9/30/202112,7633,8344,0584,428N/A
6/30/202112,4823,728N/AN/AN/A
3/31/202111,9263,5513,4963,754N/A
12/31/202011,6253,432N/AN/AN/A
9/30/202011,1923,1651,2112,724N/A
6/30/202010,7443,015N/AN/AN/A
3/31/202010,5822,9651,1992,712N/A
12/31/201910,2522,943N/AN/AN/A
9/30/201910,1193,1102,2192,599N/A
6/30/20199,9203,036N/AN/AN/A
3/31/20199,6722,908N/A2,230N/A
12/31/20189,8512,925N/AN/AN/A
9/30/20189,4422,870N/AN/AN/A
6/30/20189,2122,945N/AN/AN/A
3/31/20188,1962,941N/A2,346N/A
12/31/20178,0262,800N/AN/AN/A
9/30/20177,7812,735N/AN/AN/A
6/30/20177,2772,505N/AN/AN/A
3/31/20177,2052,468N/A2,002N/A
3/31/20165,9671,112N/A1,315N/A
3/31/20155,456892N/A901N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ERIS's forecast earnings growth (31.8% per year) is above the savings rate (6.8%).

Earnings vs Market: ERIS's earnings (31.8% per year) are forecast to grow faster than the Indian market (16.6% per year).

High Growth Earnings: ERIS's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: ERIS's revenue (14.8% per year) is forecast to grow faster than the Indian market (10.9% per year).

High Growth Revenue: ERIS's revenue (14.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ERIS's Return on Equity is forecast to be low in 3 years time (19.9%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/20 11:39
End of Day Share Price 2025/11/20 00:00
Earnings2025/09/30
Annual Earnings2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Eris Lifesciences Limited is covered by 21 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Prashant NairAmbit Capital
Ashwin MehtaAmbit Capital
Pranav ChawlaAmbit Capital